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Using phylogenetic analysis of complete virus genomes 
from human isolates obtained in Nigeria in 1966, we identi-
ﬁ  ed sylvatic dengue virus (DENV) strains from 3 febrile pa-
tients. This ﬁ  nding extends current understanding of the role 
of sylvatic DENV in febrile disease and documents another 
focus of sylvatic DENV transmission in West Africa.
S
ylvatic dengue viruses (DENVs) are ecologically and 
evolutionary distinct ancestral lineages that circulate in 
forests of Southeast Asia and West Africa between non-
human primates and arboreal Aedes mosquitoes. In Asia, 
serologic analysis and virus isolations suggest an asso-
ciation between Macaca spp. and Presbytis spp. monkeys 
and sylvatic DENV-1, -2, and -4, with Aedes niveus as the 
principal vector (1). Sylvatic DENV-3 has not been iso-
lated, but it is believed to exist in Malaysia on the basis of 
sentinel monkey seroconversions (1). In West Africa, only 
sylvatic DENV-2 has been identiﬁ  ed, where it circulates 
among Erythrocebus patas monkeys and sylvatic mosqui-
toes, including Ae. furcifer, Ae. vitattus, Ae. taylori, and Ae. 
luteocephalus (2–6).
Sylvatic DENV strains are considered the evolutionary 
progenitors of endemic and epidemic (henceforth called 
endemic) strains that are transmitted among humans in ur-
ban environments throughout the tropics and subtropics by 
the peridomestic mosquitoes Ae. aegypti and Ae. albopic-
tus. Previously, no evidence has shown that sylvatic DENV 
cycles are involved in outbreaks of human dengue, which 
involve the genetically and ecologically distinct endemic 
strains. Available data suggest that sylvatic strains are ei-
ther conﬁ  ned to forest habitats or produce relatively mild 
illness, as described in a few documented human sylvatic 
DENV-2 infections in West Africa (5,6). Additionally, the 
small number of documented human infections suggests 
that sylvatic DENV-2 strains do not produce secondary 
human infections (spillover epidemics). One possible ex-
planation for conﬁ  nement of sylvatic DENV strains to the 
forest is that they do not have contact with the peridomestic 
vectors Ae. aegypti and Ae. albopictus, which are not abun-
dant in enzootic regions.
Recent reports have shown that the gallery forest–
dwelling mosquito Ae.  furcifer  is highly susceptible to 
sylvatic DENV infection (2) and disperses from the forest 
into villages in eastern Senegal (3). This ﬁ  nding suggests 
that this species may act as a bridge vector for exchange 
between forest and peridomestic habitats. Furthermore, the 
ability of Ae. aegypti and Ae. albopictus to transmit sylvatic 
DENV (2), as well as the lack of evidence that any adapta-
tion of sylvatic DENV is needed to replicate efﬁ  ciently in 
humans (7), suggests that transfer between forest and hu-
man habitats could occur regularly.
The Study
Given the above evidence, we hypothesized that un-
recognized spillover epidemics may be caused by sylvatic 
DENV-2 strains in West Africa. We therefore examined 
isolates of DENV recovered from febrile patients, ranging 
from 3 months to 38 years of age, who were seen at the 
outpatient department of the University College Hospital, 
Ibadan, Nigeria, from August 1964 through December 1968 
(8). Complement ﬁ  xation and neutralization tests (with the 
Hawaii strain of DENV-1 and the Trinidad-1751 strain of 
DENV-2 as reference strains) classiﬁ  ed 14 of 32 original 
isolates as DENV-2 (8). Three of these 14 isolates were ob-
tained from the University of Texas Medical Branch World 
Reference Center for Emerging Viruses and Arboviruses; 
the other 11 are not known to exist in any virus collection 
(Table). 
RNA was extracted from these 3 isolates, after passage 
in C6/36 mosquito cells, by using the QIAamp Viral RNA 
Mini Kit (QIAGEN, Valencia, CA, USA). Their complete 
genomic sequences were determined by designing overlap-
ping PCR amplicons. After puriﬁ  cation by electrophoresis 
on 1% agarose gels, both strands were sequenced directly by 
using the ABI (Roche Diagnostics, Indianapolis, IN, USA) 
protocols with both the PCR and internal primers to derive 
a consensus sequence. We then generated a phylogenetic 
tree, including 22 endemic DENV-2 isolates representing 
strains from diverse localities throughout the tropics and 
neotropics, as well as representative strains of DENV-1, 
DENV-4 (including sylvatic isolates P72–1244 and P75–
215, respectively), and DENV-3 strains as outgroups (41 
sequences, 10,185 nt in length). Phylogenetic trees were in-
ferred by using Bayesian analysis with 1 million iterations 
(9) as well as maximum parsimony and neighbor-joining 
implemented in PAUP version 4.0 (10) (Figure).
All analyses indicated that all 3 Nigerian isolates were 
genetically distinct from endemic DENV-2 isolates, in-
cluding those from West Africa, and fell within the syl-
vatic DENV-2 clade (Figure). Among sylvatic isolates, 
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Malaysian and West African sylvatic DENV-2 strains were 
genetically distinct. All analyses also delineated a chrono-
logic divide among isolates within the sylvatic African 
DENV-2 clade; all pre-1980 isolates formed a group dis-
tinct from all post-1980 isolates. This observation supports 
recent evidence of rapid sylvatic DENV turnover caused 
by high nucleotide substitution rates (11). These ﬁ  ndings 
also extend the temporal and spatial range in which syl-
vatic DENV are known to circulate in West Africa. The 
ﬁ  rst documented isolation of sylvatic DENV in West Af-
rica was from a febrile patient in Senegal identiﬁ  ed in 1970 
(6); the sylvatic isolates from the Nigerian patients predate 
this Senegalese strain by 4 years.
Conclusions
The 1964–1968 DENV-2 activity among humans in 
Ibadan is epidemiologically  interesting. Although we were 
able to obtain only 3 of the of 10 DENV-2 strains collected 
in 1966 (Table), their identiﬁ  cation as sylvatic strains and 
isolation from febrile patients suggest the ﬁ  rst documented 
outbreak of sylvatic DENV-2 in humans. We deﬁ  ne out-
break as a small, localized group of affected persons; such 
groups are often conﬁ  ned to a village or a small geographic 
area. Although no written records on the location of resi-
dence or exposure of these patients exist, all resided within 
the Ibadan city limits (D.E. Carey, pers. comm.). At that 
time, humans and monkeys living within 4 diverse eco-
logic zones (rainforest, derived savannah, southern Guinea 
savannah, and plateau) in Nigeria showed high levels of 
DENV-2 neutralizing antibodies, which suggested enzo-
otic/endemic DENV-2 and a sylvatic cycle in Nigeria 30 
years ago (12,13). Furthermore, the clinical manifestation of 
dengue caused by these Nigerian sylvatic DENV-2 strains 
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Table. History of dengue virus type 2 isolates collected from patients with febrile illness in Ibadan, Nigeria, 1964–1968* 
Isolate† Patient age/sex  Source Passage history‡ Date of collection  GenBank accession no. 
IBH319 3 mo/F  Blood NA 1964 Aug 11  –
IBH10126 8 y/M  Blood NA 1966 Jun 1  –
IBH11208§ 3.5 y/F  Blood SM5, C6/36 –1  1966 Aug 17  EF105307
IBH11234§ 31 y/M  Blood SM16, C6/36 –1  1966 Aug 18  EU003591
IBH11358 5 mo/F  Blood NA 1966 Aug 24  –
IBH11444 6 y/F  Blood NA 1966 Aug 31  –
IBH11449 1.5 y/F  Blood NA 1966 Aug 31  –
IBH11664§ 1.5 y/M  Blood SM30, C6/36 –1  1966 Sep 12  EF105388
IBH11935A 13 y/M  Blood NA 1966 Sep 23  –
IBH12541 23 y/M  Serum NA 1966 Oct 17  –
IBH13028A 24 y/M  Serum NA 1966 Nov 17  –
IBH24075 1.5 y/F  Blood NA 1968 Jan 12  –
IBH26489A 5 y/M  Blood NA 1968 Apr 24  –
IBH26953 3 y/M  Blood NA 1968 May 15  –
*Available dengue virus isolates were obtained from the University of Texas Medical Branch World Reference Center for Emerging Viruses and 
Arboviruses. 
†A complete inventory of dengue viruses isolated in Ibadan during 1964–1969 is described in the 1969 annual report of the University of Ibadan, 
Arbovirus Research Project, p. 152–7. 
‡NA, not available; SM, suckling mouse; C6/36, Aedes albopictus cell line. –1 indicates that the virus isolates were passaged once in C6/36 cultures in 
our laboratory to obtain high-titer stocks. 
§Virus isolates used in this study. 
Figure. Phylogenetic relationships of 3 complete coding regions 
of Nigerian dengue virus type 2 (DENV-2) isolates obtained from 
febrile patients in Ibadan, Nigeria, during the 1966 rainy season. 
A total of 15 sylvatic DENV-2 genomes (shaded) were compared 
with human isolates of DENV-2 and representatives of DENV-1, 
DENV-3, and DENV-4. Phylogeny was inferred by using Bayesian 
analysis, and all horizontal branches are scaled according to the 
number of substitutions per site. Bootstrap values are shown for 
key nodes.was indistinguishable from classic dengue fever caused by 
endemic strains (D.E. Carey, pers. comm.) (5,6,14). Isola-
tion of sylvatic DENV-2 from febrile patients in an urban 
environment (8), the ability of peridomestic Aedes spp. 
mosquitoes (Ae. aegypti and Ae. albopictus) to serve as 
vectors for similar West African strains (2), and the lack of 
evidence that any adaptation of sylvatic DENV is needed 
to replicate efﬁ  ciently in humans (7) suggest that spillover 
epidemics occur in urban settings. 
Currently, limited availability of reliable epidemio-
logic information and inability to differentiate clinically 
or serologically between urban and sylvatic DENV-2 in-
fection prevent an accurate assessment of the true extent 
of human exposure in West Africa. Thus, further study 
is needed to elucidate the interactions of sylvatic and ur-
ban transmission. Even with functional reporting and sur-
veillance, clinical diagnosis of dengue in West Africa is 
complicated by cocirculation of several other viruses that 
cause clinically similar febrile diseases (e.g., chikungunya, 
o’nyong-nyong, Zika viruses) (15). Other obstacles to ac-
curate assessment of the public health effect of sylvatic 
DENV in Africa include limited access of the population to 
healthcare facilities, lack of access to viral and serologic di-
agnostics, popular beliefs that discourage standard medical 
treatment unless illness is severe, and a lack of surveillance 
of monkeys. To overcome these obstacles, comprehensive 
ecologic and epidemiologic studies are needed to assess the 
roles of nonhuman primates and other vertebrate hosts in 
the maintenance of sylvatic DENV, the degree and routes 
of ecologic contact between humans and sylvatic DENV, 
and the replication and immunologic dynamics of sylvatic 
DENV in nonhuman primates.
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